165893-99-2

Basic information

• Product Name: 2,5-Dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione
• Synonyms: 2,5-DIBENZYL-TETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE;2,5-Dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione;Pyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione, tetrahydro-2,5-bis(phenylMethyl)-;2,5-dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione(WXC01899)
• CAS NO: 165893-99-2
• Molecular Formula: C₂₀H₂₀N₂O₂
• Molecular Weight: 320.39
• Mol File: 165893-99-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 520.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.258±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 7.29±0.20(Predicted)
• CAS DataBase Reference: 2,5-Dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione(165893-99-2)
• EPA Substance Registry System: 2,5-Dibenzyltetrahydropyrrolo[3,4-c]pyrrole-1,3-dione(165893-99-2)

Safety Data

• Hazardous Substances Data: 165893-99-2(Hazardous Substances Data)

Usage

Uses

2,5-DIBENZYL-TETRAHYDROPYRROLO[3,4-C]PYRROLE-1,3(2H,3AH)-DIONE is a CCR5 antagonist.

Upstream product

• 50-00-0 formaldehyd 
• 1631-26-1 1-benzyl-1H-pyrrole-2,5-dione 
• 7689-50-1 N-benzyl glycine hydrochloride 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 103-01-5 N-Phenylglycine 
• 17136-36-6 N-benzylglycine 
• 93102-06-8 N-benzyl-N-(butyloxymethyl)trimethylsilylmethylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 86732-22-1 2-benzyloctahydropyrrolo[3,4-c]pyrrole 

Downstream Products

• 172739-04-7 cis-3-benzyl-3,7-diazabicyclo[3.3.0]octane 
• 848591-86-6 5-benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione 
• 86732-32-3 N-benzyltetrahydro-1H-pyrrole-3,4-dicarboximide 
• 165894-00-8 2,5-Dibenzyl-octahydro-pyrrolo[3,4-c]pyrrole 

Relevant articles and documents

Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists

Starting with a high-throughput screening lead, a novel series of CCR5 antagonists was developed utilizing an information-based approach. Improvement of pharmacokinetic properties for the series was pursued by SAR exploration of the lead template. The synthesis, SAR and biological profiles of the series are described.

Rifamycin derivatives

Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.

BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES

Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro-or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2-and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.